Discovering the next breakout biotech company can be a monumental task for investors. Those who follow the industry have witnessed a number of biotech stocks posting incredible gains. Intercept Pharmaceuticals (NASDAQ:ICPT) is probably one that will be talked about for years to come. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (NYSEARCA:FXR). On January 9th Intercept announced that the FLINT trial of obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) had been stopped early based on a planned interim analysis showing that the primary endpoint of the trial had been met. The news was followed by an explosion in...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|